| Active Market | Forge Price1 | Last Funding Round | Trade Eligibility | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Company | Sector & Subsector | Market Activity4   |
Highest Bid | Lowest Ask | Last Matched | +/- to LFR | $ Total Bids |
$ Total Asks |
# Bids |
# Asks |
Current Price |
6-month |
1-year |
Total Funding |
Round | Date | Amount Raised |
Post-Money Valuation3 |
Price |
Key Investors | Common | Preferred | Fund | ||
 | Nusano | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $474.68M | Series D-1 | 4/21/2026 | $180M | $655.01M | $1.25 | Undisclosed Investors | ||||
 | Soufflé Therapeutics | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $330.79M | Series B | 7/21/2026 | $134.76M | $506.77M | $2.70 | Undisclosed Investors | ||||
 | Cellanome | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $307.18M | Series C | 12/22/2025 | $90.84M | $712.61M | $8.49 | Undisclosed Investors | ||||
 | Equip | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $144.89M | Series D | 9/16/2025 | $47.89M | $863.1M | $29.89 | Kerry Washington, Pledge Ventures | ||||
 | Iambic Therapeutics | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $336.52M | Series B-4 | 4/1/2026 | $27.77M | $664.28M | $3.26 | Undisclosed Investors | ||||
 | Anumana | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $185.3M | Series C | 4/24/2025 | $95.4M | $568.24M | $5.16 | Boston Scientific Corporation, Matrix Capital, Mayo Clinic, Matrix Partners, NTTVC | ||||
 | CG Oncology | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $510.76M | Series F | 8/2/2023 | $105.02M | $615.24M | $1.29 | Foresite Capital, TCGX, Avidity Partners, BVF Partners, Janus Henderson Investors, Acorn Bioventures, Ally Bridge Group, Decheng Capital, Longitude Capital, Malin Corporatoin, RA Capital Management | ||||
 | DNAnexus | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $1.14B | Series I | 3/8/2022 | $200M | $616.31M | $0.61 | Blackstone Growth, Northpond Ventures, GV, Perceptive Advisors, Innovatus Capital Partners, Foresite Capital | ||||
 | ModMed | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $336.59M | Series F | 5/10/2017 | $235.96M | $962.09M | $1.05 | Warburg Pincus | ||||
 | OncoC4 | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $131.23M | Series B | 10/2/2025 | $50M | $619.93M | $4.66 | Greater Bay Area Homeland Investments, HM Capital, 3E Bioventures Capital, Kaitai Capital | ||||
 | Paige | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $247.3M | Series C-1 | 3/2/2023 | $19.5M | $656.14M | $25.74 | Undisclosed Investors | ||||
 | RapidAI | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $93.84M | Series C | 7/27/2023 | $75M | $667.51M | $55.44 | Vista Equity Partners | ||||
 | AcuityMD | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $163.77M | Series C | 4/21/2026 | $80M | $955M | $8.99 | StepStone Group, Benchmark, Redpoint Ventures, ICONIQ Growth, Atreides Management | ||||
 | AliveCor | Healthcare Medical Devices | Low | $xx.xx | $xx.xx | $xx.xx | xx% | -- | $500.00K | -- | 1 | Not available | -- | -- | $277.15M | Series F | 8/16/2022 | $150M | $943.68M | $14.72 | GE Healthcare, NGK-NTK, Khosla Ventures, Bold Capital Partners, Qualcomm Ventures, WP Global Partners | ||||
 | Capstan Therapeutics | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $845M | Series B | 3/20/2024 | $175M | $525.33M | $3.37 | RA Capital Management, Forbion, Johnson & Johnson, Mubadala Capital, Perceptive Advisors, Sofinnova Investments, Alexandria Venture Investments, Bristol Myers Squibb, Eli Lilly, Bayer, Novartis Venture Fund, OrbiMed, Pfizer Ventures, Polaris Partners, Vida Ventures | ||||
 | Cellarity | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $435.63M | Series D | 12/23/2024 | $196.06M | $517.83M | $3.60 | Undisclosed Investors | ||||
 | Cleerly | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $386.48M | Series C | 12/4/2024 | $330.08M | $729.01M | $11.78 | T. Rowe Price Associates, Fidelity Management, Sands Capital, Piper Sandler, Heartland Healthcare Capital funds, Mirae Asset Capital, Peter Thiel, Breyer Capital, Novartis, Pura Vida Investments, Vensana Capital, LRVHealth, New Leaf Ventures, Cigna Ventures, DigiTx Partners, Insight Partners, Battery Ventures | ||||
 | Latigo Bio | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $287.9M | Series B | 3/17/2025 | $150M | $525.73M | $1.57 | Blue Owl Capital, Deep Track Capital, Access Biotechnology, Qatar Investment Authority, Cormorant Asset Management, Sanofi Ventures, Rock Springs Capital, UPMC Enterprises, Kern Capital, Westlake Village BioPartners, Foresite Capital, 5AM Ventures, Alexandria Venture Investments | ||||
 | Rakuten Medical | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $874.92M | Series F-3 | 1/7/2026 | $3.6M | $636.9M | $1.03 | Taiwania Capital, Axil Capital Group, Daiwa Securities, Mitsui Sumitomo Insurance Company, Sumitomo Mitsui Banking, ABIES Capital, Nexus CVC, OEP Group, SBI Group, Rakuten, Mickey Mikitani | ||||
 | Cerapedics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $163.58M | Series G | 6/5/2024 | $15.23M | $744.31M | $5.64 | Undisclosed Investors | ||||
 | TraceLink | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $278.43M | Series D | 8/21/2018 | $60M | $657M | $16.01 | Georgian Partners, Vulcan Capital, Willett Advisors, FirstMark Capital, Volition Capital, F-Prime Capital, Goldman Sachs | ||||
 | Valo | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $406.25M | Series B | 3/9/2021 | $310M | $919.92M | $5.88 | PSP Investments, Flagship Pioneering, Invus Public Equities, HBM Healthcare Investments, Atinum Investment, Mirae Asset Capital, Koch Disruptive Technologies | ||||
 | Avenzo Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $445.85M | Series B | 9/22/2025 | $60M | $616.96M | $2.22 | OrbiMed, SR One, Longwood Fund, Foresite Capital, Lilly Asia Ventures, Surveyor Capital, NEA, Deep Track Capital, Sofinnova Investments, Sands Capital, INCE Capital, TF Capital, Delos Capital, Quan Capital | ||||
 | Axtria | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $159.97M | Series E | 5/13/2021 | $100.1M | $920.88M | $9.53 | Bain Capital Tech Opportunities | ||||